Insider Selling: Zoetis Inc (ZTS) EVP Sells 6,123 Shares of Stock

Zoetis Inc (NYSE:ZTS) EVP Clinton A. Jr. Lewis sold 6,123 shares of the business’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $101.90, for a total value of $623,933.70. Following the transaction, the executive vice president now directly owns 51,926 shares of the company’s stock, valued at approximately $5,291,259.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

ZTS traded down $0.82 on Friday, reaching $102.11. The stock had a trading volume of 112,243 shares, compared to its average volume of 1,922,895. Zoetis Inc has a fifty-two week low of $78.90 and a fifty-two week high of $103.97. The company has a quick ratio of 2.79, a current ratio of 4.05 and a debt-to-equity ratio of 2.84. The stock has a market cap of $48.75 billion, a PE ratio of 32.60, a PEG ratio of 2.55 and a beta of 0.91.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 2nd. The company reported $0.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.09. Zoetis had a return on equity of 73.66% and a net margin of 23.47%. The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.45 billion. During the same quarter in the prior year, the firm earned $0.75 EPS. The business’s revenue for the quarter was up 6.5% compared to the same quarter last year. On average, equities research analysts expect that Zoetis Inc will post 3.48 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 19th will be issued a $0.164 dividend. The ex-dividend date of this dividend is Thursday, July 18th. This represents a $0.66 dividend on an annualized basis and a yield of 0.64%. Zoetis’s payout ratio is presently 21.09%.

A number of equities analysts have recently commented on ZTS shares. UBS Group started coverage on Zoetis in a report on Wednesday, January 23rd. They set a “neutral” rating and a $86.00 price target for the company. Zacks Investment Research cut Zoetis from a “hold” rating to a “sell” rating in a report on Saturday, January 19th. Credit Suisse Group boosted their price target on Zoetis from $102.00 to $112.00 and gave the stock an “outperform” rating in a report on Tuesday, April 2nd. Stifel Nicolaus raised Zoetis from a “hold” rating to a “buy” rating and boosted their price target for the stock from $97.00 to $110.00 in a report on Monday, March 4th. Finally, SunTrust Banks started coverage on Zoetis in a report on Tuesday, March 19th. They set a “hold” rating and a $100.00 price target for the company. Six analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $103.15.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Farmers & Merchants Trust Co of Chambersburg PA acquired a new stake in shares of Zoetis in the first quarter valued at about $25,000. Glassman Wealth Services increased its stake in shares of Zoetis by 306.5% in the first quarter. Glassman Wealth Services now owns 252 shares of the company’s stock valued at $25,000 after buying an additional 190 shares during the period. Berman Capital Advisors LLC acquired a new stake in shares of Zoetis in the fourth quarter valued at about $26,000. Private Ocean LLC acquired a new stake in shares of Zoetis in the first quarter valued at about $27,000. Finally, Athena Capital Advisors LLC acquired a new stake in shares of Zoetis in the fourth quarter valued at about $29,000. 90.78% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Story: Calculate Your Return on Investment (ROI)

Insider Buying and Selling by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with's FREE daily email newsletter.